bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
Article Date
June 16, 2025
This article is featured on another website.
Go to article
March 26, 2026
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
March 26, 2026
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…